M&A / Deals EverSea Medicines to acquire Hasten Biopharmaceuticals Pharmaceutical Business ReviewThe acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. M&A / DealsRead full story Post navigation Previous: Jeito Capital secures over $1.2bn for new biopharma investmentsNext: 23andMe study explains variable results with obesity drugs Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
